Prolight Diagnostics (“Prolight”) today announced that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance that its high-sensitivity immunoassay is capable of reproducibly detecting low levels of specific proteins in a digital manner.
“This is a very important step on our journey to develop a high-sensitivity assay for digitally detecting troponin. Such an assay that is uniquely developed for point-of-care testing would be very valuable when detecting and diagnosing heart attack,” said Ulf Bladin, CEO of Prolight Diagnostics.
Using human plasma samples, thyroid stimulating hormone (TSH) levels were measured down to single digit nanogram per liter (ng/L) with laboratory grade reproducibility. These concentrations are indicative of those required for rule out of myocardial infarction using high-sensitivity troponin assays, in line with the European Cardiology Society’s Guidelines on Fourth Universal Definition of Myocardial Infarction.
“The impressive results mean that we are now ready to take the next step in developing our high-sensitive troponin assay. The speed at which we were able to reach this sensitivity and reliability with our first digital immunoassay, bodes well also for the development of many other assays in large indication areas,” said Ulf Bladin.
